| scholarly article | Q13442814 |
| P50 | author | Scott A. Wildman | Q38802377 |
| James W. Janetka | Q38802400 | ||
| P2093 | author name string | Zhenfu Han | |
| Lidija Klampfer | |||
| Tommy Kim | |||
| Partha Karmakar | |||
| Peter K W Harris | |||
| Ben Y Owusu | |||
| P2860 | cites work | Cross-talk between the proto-oncogenes Met and Ron | Q22254408 |
| Structural insight into distinct mechanisms of protease inhibition by antibodies | Q27649305 | ||
| Unraveling the allosteric mechanism of serine protease inhibition by an antibody | Q27658583 | ||
| A Reverse Binding Motif That Contributes to Specific Protease Inhibition by Antibodies | Q27676066 | ||
| Discovery of Pyridyl Bis(oxy)dibenzimidamide Derivatives as Selective Matriptase Inhibitors | Q27684175 | ||
| Discovery of O-(3-carbamimidoylphenyl)-l-serine amides as matriptase inhibitors using a fragment-linking approach | Q27697286 | ||
| Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction | Q27860958 | ||
| Proteolytic activation of pro-macrophage-stimulating protein by hepsin. | Q27865259 | ||
| Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets | Q28081193 | ||
| Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease | Q28144714 | ||
| Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers | Q31161402 | ||
| Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. | Q33518855 | ||
| Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy | Q33652455 | ||
| Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors | Q33769437 | ||
| An allosteric anti-hepsin antibody derived from a constrained phage display library | Q34132742 | ||
| Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator. | Q34379859 | ||
| A history of cancer chemotherapy | Q34869530 | ||
| Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets. | Q35604797 | ||
| Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway | Q35719884 | ||
| Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils | Q36038823 | ||
| Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells | Q36223889 | ||
| Mechanisms of resistance to EGFR tyrosine kinase inhibitors | Q36238664 | ||
| Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder | Q36615866 | ||
| SPINT2 Deregulation in Prostate Carcinoma | Q36737100 | ||
| Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines | Q37275734 | ||
| Targeting MET in cancer: rationale and progress | Q37978193 | ||
| MSP-RON signalling in cancer: pathogenesis and therapeutic potential | Q38116308 | ||
| Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress | Q38169807 | ||
| Targeting the oncogenic Met receptor by antibodies and gene therapy | Q38216590 | ||
| Mechanisms of hepatocyte growth factor activation in cancer tissues | Q38255480 | ||
| Hepatocyte growth factor activator inhibitor type‑1 in cancer: advances and perspectives (Review). | Q38259598 | ||
| Clinical and biological significance of hepsin overexpression in breast cancer. | Q38411489 | ||
| Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation | Q38433828 | ||
| Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update | Q38669280 | ||
| c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. | Q38826543 | ||
| Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors | Q38831317 | ||
| Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines | Q38885876 | ||
| Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation | Q39434507 | ||
| HGF-induced DU145 cell scatter assay | Q39508346 | ||
| Strong expression association between matriptase and its substrate prostasin in breast cancer | Q39523621 | ||
| Ron kinase transphosphorylation sustains MET oncogene addiction | Q39611289 | ||
| Design and synthesis of potent, selective inhibitors of matriptase. | Q39734758 | ||
| Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma | Q39787985 | ||
| Collaboration of RON and epidermal growth factor receptor in human bladder carcinogenesis. | Q40214759 | ||
| Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. | Q40443024 | ||
| Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer | Q42837140 | ||
| The hepatocyte growth factor regulatory factors in human breast cancer | Q44735694 | ||
| Hepatocyte growth factor activator is a serum activator of single-chain precursor macrophage-stimulating protein. | Q46003940 | ||
| In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design | Q46383079 | ||
| The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer | Q46553705 | ||
| Cancer chemotherapy: a critical analysis of its 60 years of history | Q48449340 | ||
| Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression. | Q54254288 | ||
| Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity | Q67543328 | ||
| Proteolytic cleavage and activation of pro-macrophage-stimulating protein and upregulation of its receptor in tissue injury | Q77386429 | ||
| Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase | Q79842080 | ||
| Analysis of subpocket selectivity and identification of potent selective inhibitors for matriptase and matriptase-2 | Q85942507 | ||
| New 3-amidinophenylalanine-derived inhibitors of matriptase | Q104520902 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 585-599 | |
| P577 | publication date | 2016-02-17 | |
| P1433 | published in | ChemMedChem | Q2962252 |
| P1476 | title | α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer | |
| P478 | volume | 11 |
| Q90141187 | Cell surface-anchored serine proteases in cancer progression and metastasis |
| Q38831784 | Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment |
| Q60920626 | Hepatocyte growth factor activator inhibitor-2 stabilizes Epcam and maintains epithelial organization in the mouse intestine |
| Q39816968 | Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q41825773 | Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. |
| Q39274990 | The c-Met receptor: Implication for targeted therapies in colorectal cancer |
| Q39015415 | The role of type II transmembrane serine protease-mediated signaling in cancer |
Search more.